Luisa Hector
Stock Analyst at Berenberg Bank
(3.66)
# 2,019
Out of 4,345 analysts
288
Total ratings
58.2%
Success rate
5.2%
Average return
Main Sectors:
Stocks Rated by Luisa Hector
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintained: Buy | $275 | $215.40 | +27.67% | 18 | May 8, 2026 | |
| SWX: ROP Roche Holding AG | Maintained: Hold | CHF 340.00 | $330.90 | +2.75% | 52 | May 8, 2026 | |
| EPA: SAN Sanofi | Maintained: Buy | €105.00 | $77.14 | +36.12% | 50 | May 6, 2026 | |
| LON: AZN AstraZeneca PLC | Rated: Buy | 17,000p | $14,008.00 | +21.36% | 69 | Mar 16, 2026 | |
| SWX: NOVN Novartis AG | Rated: Hold | CHF 92.00 → CHF 110.00 | $119.58 | -8.01% | 4 | Mar 6, 2026 | |
| MRK Merck & Co. | Maintained: Hold | $95 → $115 | $120.24 | -4.36% | 33 | Feb 27, 2026 | |
| LON: BTRW Barratt Redrow plc | Maintained: Hold | 414p | $265.00 | +56.23% | 1 | Feb 11, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Buy | kr 400.00 → kr 415.00 | $285.40 | +45.41% | 7 | Jan 16, 2026 | |
| LON: GSK GSK plc | Maintained: Hold | 1,660p | $1,939.50 | -14.41% | 7 | Jan 6, 2026 | |
| SNY Sanofi | Maintained: Buy | $63 → $67 | $44.43 | n/a | 11 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $55 → $60 | $57.52 | n/a | 18 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $444.00 | n/a | 1 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €197.00 | $129.50 | n/a | 13 | Feb 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $43 | $26.21 | n/a | 1 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €77.36 | $38.12 | n/a | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $10.99 | n/a | 2 | Sep 15, 2016 |
AbbVie
May 8, 2026
Maintained: Buy
Price Target: $275
Current: $215.40
Upside: +27.67%
Roche Holding AG
May 8, 2026
Maintained: Hold
Price Target: CHF 340.00
Current: $330.90
Upside: +2.75%
Sanofi
May 6, 2026
Maintained: Buy
Price Target: €105.00
Current: $77.14
Upside: +36.12%
AstraZeneca PLC
Mar 16, 2026
Rated: Buy
Price Target: 17,000p
Current: $14,008.00
Upside: +21.36%
Novartis AG
Mar 6, 2026
Rated: Hold
Price Target: CHF 92.00 → CHF 110.00
Current: $119.58
Upside: -8.01%
Merck & Co.
Feb 27, 2026
Maintained: Hold
Price Target: $95 → $115
Current: $120.24
Upside: -4.36%
Barratt Redrow plc
Feb 11, 2026
Maintained: Hold
Price Target: 414p
Current: $265.00
Upside: +56.23%
Novo Nordisk A/S
Jan 16, 2026
Maintained: Buy
Price Target: kr 400.00 → kr 415.00
Current: $285.40
Upside: +45.41%
GSK plc
Jan 6, 2026
Maintained: Hold
Price Target: 1,660p
Current: $1,939.50
Upside: -14.41%
Sanofi
May 16, 2025
Maintained: Buy
Price Target: $63 → $67
Current: $44.43
Upside: n/a
Dec 10, 2024
Maintained: Hold
Price Target: $55 → $60
Current: $57.52
Upside: n/a
Feb 28, 2024
Upgraded: Buy
Price Target: n/a
Current: $444.00
Upside: n/a
Feb 10, 2022
Maintained: Hold
Price Target: €197.00
Current: $129.50
Upside: n/a
Jun 14, 2021
Maintained: Hold
Price Target: $43
Current: $26.21
Upside: n/a
Sep 11, 2018
Maintained: Hold
Price Target: €77.36
Current: $38.12
Upside: n/a
Sep 15, 2016
Reiterated: Hold
Price Target: n/a
Current: $10.99
Upside: n/a